Atlas Trials

Disitamab Vedotin Combined With Fruquintinib for mCRC With HER2 Expression

Clinical trial NCT05661357 · UNKNOWN

Trial details

NCT number
NCT05661357
Sponsor
Zhongnan Hospital
Status
UNKNOWN
Phase
Phase 4
Study type
INTERVENTIONAL
HER2Colorectal Cancer
Start date
2023-01-01
Primary completion
2025-01-31
Enrollment
51

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.